Direct oral anticoagulants vs low-molecular-weight heparins for cancer-associated thromboembolism

doi:10.12998/wjcc.v14.i17.118087

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 17

This Article

(27)

(44)

(0)

(929)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Cases. Jun 16, 2026; 14(17): 118087
Published online Jun 16, 2026. doi: 10.12998/wjcc.v14.i17.118087

Full Size Figure Download Figure

Figure 3 Forest plot of deep venous thrombosis. RR: Risk ratio; CI: Confidence interval.

Citation: Haider F, Ahmed F, Junaid Y, Khalid M, Dar A, Arham M, Ullah A, Aliha S, Arshad MU, Naeem K, Ali Hashim MM, Gohar N, Ricciuti A, Bhanderi V, Alenezi F, Patel B. Direct oral anticoagulants vs low-molecular-weight heparins for cancer-associated thromboembolism. World J Clin Cases 2026; 14(17): 118087
URL: https://www.wjgnet.com/2307-8960/full/v14/i17/118087.htm
DOI: https://dx.doi.org/10.12998/wjcc.v14.i17.118087

Haider F, Ahmed F, Junaid Y, Khalid M, Dar A, Arham M, Ullah A, Aliha S, Arshad MU, Naeem K, Ali Hashim MM, Gohar N, Ricciuti A, Bhanderi V, Alenezi F, Patel B. Direct oral anticoagulants vs low-molecular-weight heparins for cancer-associated thromboembolism. World J Clin Cases 2026; 14(17): 118087 [DOI: 10.12998/wjcc.v14.i17.118087]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.